课题基金 / 基金详情

90YCC49 MONOCLONAL ANTIBODY IN ADVANCED NONSMALL CELL LUNG CANCER

90YCC49 MONOCLONAL ANTIBODY IN ADVANCED NONSMALL CELL LUNG CANCER
90YCC49 单克隆抗体治疗晚期非小细胞肺癌
批准号：
6303037
负责人：
FRANCISCO ROBERT
金额：
$2.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6303037
关键词：
clinical research clinical trial phase I combination cancer therapy combination chemotherapy dosage drug adverse effect drug screening /evaluation ethylenediaminetetraacetate human subject human therapy evaluation immunotherapy interferon alpha monoclonal antibody neoplasm /cancer chemotherapy nonsmall cell lung cancer pharmacokinetics

项目摘要

项目成果

FRANCISCO ROBERT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a Phase I study of 90Y-labeled anti-tag 72 murine (CC49) monoclonal antibody in patients with advanced non-small cell lung cancer. The primary objective of the study was to determine the MTD and dose-limiting toxicities of 90Y-CC49. Secondary objective was to determine if certain chilators (EDTA or DPTA) could decrease myelosuppression, and to exclude the concomitant infusion of Taxol with 90Y-CC49. Dose limiting toxicity was myelosuppression (grade 4 thromboctopenia and neutropenia). The MTD was exceeded with dose of 17mg/m2. There was adequate imaging with IN-CC49, and the TY2 was approximately 47 + 3 hours (one compartment model.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA
EGFR ANTIBODY 225 IN METASTATIC RENAL CELL CARCINOMA
PNU 214936 IN ADVANCED NON SMALL CELL LUNG CANCER
ONCONASE VS DOXORUBICIN IN MALIGNANT MESOTHELIOMA
海外基金